P
PALISADE BIO INC
NASDAQ: PALI (Palisade Bio, Inc.)
Last update: 11 minutes ago1.13
-0.03 (-2.59%)
| Previous Close | 1.16 |
| Volume | 2,029,638 |
| Price / Sales | 396.32 |
| Price / Book | 1.78 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -6.07 |
| Total Debt/Equity (MRQ) | 1.09% |
| Current Ratio (MRQ) | 2.84 |
| Operating Cash Flow (TTM) | -11.35 M |
| Levered Free Cash Flow (TTM) | -7.37 M |
| Return on Assets (TTM) | -80.94% |
| Return on Equity (TTM) | -170.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Palisade Bio, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.42 |
Select this tab to load the latest available analysis.
|
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 5.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Soleus Capital Management, L.P. | 30 Jun 2026 | 13,063,687 |
| Ameriprise Financial Inc | 30 Jun 2026 | 11,081,434 |
| Janus Henderson Group Ltd. | 31 Mar 2026 | 10,689,452 |
| Jupiter Topco Llc | 30 Jun 2026 | 10,689,452 |
| Octagon Capital Advisors Lp | 30 Jun 2026 | 10,276,317 |
| Perceptive Advisors Llc | 30 Jun 2026 | 8,425,065 |
| Ra Capital Management, L.P. | 30 Jun 2026 | 7,124,116 |
| Franklin Templeton Inc | 30 Jun 2026 | 5,785,189 |
| Point72 Asset Management, L.P. | 30 Jun 2026 | 5,253,403 |
| Boxer Capital Management, Llc | 30 Jun 2026 | 4,799,875 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 4,500,000 |
| Eversept Partners, Lp | 30 Jun 2026 | 4,182,785 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |